Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005.

[1]  B. Strauer,et al.  Periphere arterielle Komplikationen nach Herzkatheteruntersuchung , 1998, Herz.

[2]  R. Groom,et al.  Intraoperative Red Blood Cell Transfusion During Coronary Artery Bypass Graft Surgery Increases the Risk of Postoperative Low-Output Heart Failure , 2006, Circulation.

[3]  Deepak L. Bhatt,et al.  CORONARY ARTERY DISEASE Original Studies Correlates and Outcomes of Retroperitoneal Hemorrhage Complicating Percutaneous Coronary Intervention , 2006 .

[4]  Sunil V. Rao,et al.  Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions , 2006, Journal of Thrombosis and Thrombolysis.

[5]  A. Yeung,et al.  Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. , 2005, Journal of the American College of Cardiology.

[6]  B. McDonald,et al.  Clinical consequences of anemia and red cell transfusion in the critically ill. , 2004, Critical care clinics.

[7]  M. Müllner,et al.  Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. , 2004, JAMA.

[8]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[9]  B. Starnes,et al.  Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device. , 2003, Journal of vascular surgery.

[10]  B. Gersh,et al.  Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. , 2003, American heart journal.

[11]  W. Ghali,et al.  In-hospital outcomes after percutaneous coronary intervention in Canada: 1992/93 to 2000/01. , 2003, The Canadian journal of cardiology.

[12]  T. Ryan,et al.  Predicting vascular complications in percutaneous coronary interventions. , 2003, American heart journal.

[13]  N. Caplice,et al.  Infectious and Ischemic Complications from Percutaneous Closure Devices Used after Vascular Access , 2003, Annals of vascular surgery.

[14]  T. Ryan,et al.  Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. , 2002, Journal of the American College of Cardiology.

[15]  M. Bell,et al.  Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. , 2001, Mayo Clinic proceedings.

[16]  W. Weintraub,et al.  Trends in outcome and costs of coronary intervention in the 1990s. , 2001, The American journal of cardiology.

[17]  C. Moore,et al.  Complications of femoral artery closure devices , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[19]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[20]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[21]  B. Strauer,et al.  [Peripheral arterial complications after heart catheterization]. , 1998, Herz.

[22]  R. Califf,et al.  Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. , 1998, The American journal of cardiology.

[23]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[24]  W. Barr,et al.  Femoral artery catheterization complications: a study of 503 consecutive patients. , 1995, Catheterization and cardiovascular diagnosis.

[25]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[26]  E. Topol,et al.  Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. , 1993, Journal of the American College of Cardiology.